Table 1.

 Overview of the A-Ms studied

Target	Drug	Abbreviation	Clinical status	% clinical response	Primary dose studied, nM	IFN detected?
MT dynamics	Docetaxel	DTX	First-line therapy	Ovarian: 25 to 41; NSCLC: 19 to 25; head and neck: 32 to 42	10	Yes
MPS1	BAY-1217389 CFI-402257	MPS1i_1 MPS1i_2	In clinical trials	NA	20 750	Yes
Aurora B kinase	Barasertib	AurkBi	Failed trials	0	250	No
Aurora A kinase	Alisertib	AurkAi	Failed trials	0, 1	150	No
Pan-Aurora kinase	Tozasertib	Pan-Aurki	Failed trials	0	250	No
Polo-like kinase 1	Volasertib	PLK1i	Failed trials	4.6	100	No
Centromere protein E	GSK-923295	CenpEi	Failed trials	3	250	No
Kif11	Ispinesib	Kif11i	Failed trials	0, 0	2.5	No
Bub1	BAY-1816032	Bub1i	Preclinical	N/A	1,000	No
Haspin	CHR-6494	Haspini	Preclinical	N/A	250	No

The table describes the drug targets, drug names, drug abbreviations, clinical status, select reported clinical response rates, the typical experimental dose studied in this article, and our own observations of IFN induction. Percent clinical response refers to objective response (combined complete and partial responses as defined by RECIST scoring) as a monotherapy in solid tumors (35–37). The primary doses studied refer to the concentrations used in our experiments when dose–responses are not shown and unless otherwise noted. These doses are based on literature values and our own observations. IFN detected refers to whether we observed IFN signal in the coculture assay with BJ WT cells. N/A: not applicable; NSCLC: non-small cell lung cancer.